PTS Diagnostics Announces New Retail Point-of-Care Software

PTS Diagnostics Announces New Retail Point-of-Care Software

PTS Connect ProLink® platform expands connectivity and informatics offerings

INDIANAPOLIS (Jan. 4, 2018) – PTS Diagnostics, a U.S.–based manufacturer of point-of-care biometric testing devices, today announced that they are releasing PTS Connect ProLink, a cloud-based biometric data collection and transfer software platform that helps retail partners’ pharmacies and clinics provide valuable health screening services to their customers.

Unlike other data capture systems, PTS Connect ProLink delivers a personalized wellness report through wireless technology. The solution seamlessly and instantly transfers test results from PTS Diagnostic’s CardioChek® PA and CardioChek Plus analyzers to a secure online portal.

“Basic health and wellness data is most effective when delivered to the patient as part of a face-to-face consultation,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “This new connectivity platform combined with our proven point-of-care solutions allows us to better serve both the healthcare provider and those impacted by chronic diseases.”

The software, developed by Cystelcom Sistemas, S.A., is powered by the company’s mHealthAlert software. It combines original hardware with intuitive software that wirelessly receives and securely stores biometric data from various diagnostics devices. All this can be done using any modern iOS, Android or Windows computer as well as mobile phones and tablets.

“The mHealthAlert software, developed specifically for retail pharmacies and clinics, is the engine that drives PTS Connect ProLink,” said Manuel Cuenca, CEO of Cystelcom Sistemas, S.A. “We’re proud to partner with a forward-thinking company such as PTS Diagnostics. Together, we will craft a niche in the ever-growing field of population health management.”

As pharmacy-based retail clinics continue to become key players in today’s healthcare market, many are looking to stay ahead of the curve by offering critical health screening services in-store. PTS Connect ProLink provides a solution designed with retail screeners in mind, offering benefits such as:
  • Increased traffic by offering quick, convenient, wellness screening services
  •  Personalized, printable wellness reports including company logo
  • HIPAA-compliant data on the health needs of customers
  • PTS Connect ProLink is available in the United States and abroad. To learn more, reach out to a PTS Diagnostics’ area sales manager, email CustomerService@ptsdiagnostics.com, or call 877- 870-5610 (toll-free in the U.S.).

    About PTS Diagnostics:
    Through its People, Technology and Service, PTS Diagnostics creates health innovation that drives action and results. Since 1992, we have helped medical professionals and patients achieve better health outcomes through our accurate, precise, fast, affordable, and certified point-of-care medical devices. Healthcare professionals have used our CardioChek products to assess cardiovascular disease risks for more than 140 million patients worldwide through lipid panel screening. And, our A1CNow® systems, which provide fast and reliable HbA1c testing, have helped physicians deliver more effective treatments to patients with diabetes. From our headquarters in the United States of America, we design, manufacture, and market our products to more than 140 countries around the globe. For more information, visit ptsdiagnostics.com.

    About Cystelcom Sistemas, S.A:
    Cystelcom has been focused on providing software solutions since 1993. The company’s interest in healthcare began when Cystelcom’s founder, Mr. Manuel Cuenca, identified the need to share biometric data from his father who was ill to his father’s doctors. As a consequence, mHealthAlert was developed using Artificial Intelligence algorithms to help track patients with various illnesses and a fully functioning portal focused on patient wellness. Cystelcom has teamed with large companies such as Cisco, SAP, Vodafone, Fujitsu, and many hospitals in the EU. Headquartered in Madrid, Spain, Cystelcom continues to grow and serve its markets with a keen eye on the patient’s health.

    Press Contact:
    Ryan Simpson, Marketing Associate
    317-870-5610
    rsimpson@ptsdiagnostics.com

    PTS Diagnostics Opening New Global Headquarters, Poised to Continue Record Growth

    PTS Diagnostics Opening New Global Headquarters, Poised to Continue Record Growth

    Private groundbreaking ceremony was held on Tuesday, May 15 in Whitestown

    INDIANAPOLIS (May 24, 2018) – PTS Diagnostics, a U.S.–based manufacturer of point-of-care biometric testing devices, today announced that they are expanding operations in Indianapolis and building a new global headquarters.

    In order to support continued rapid growth, the in vitro diagnostics company is investing in additional manufacturing and office space, and moving their global headquarters to Whitestown. The new 135,000 square foot building is slated to open in June of 2019 on the southwest corner of Anson Blvd and C.R. 450 South.

    A private groundbreaking ceremony with executives, architects, builders and representatives from PTS Diagnostics’ parent company, Sinocare, was held on the morning of Tuesday, May 15. A company-wide celebration is planned for summer 2018.

    “PTS Diagnostics is still in high-growth mode, and our organization has evolved considerably in the past decade,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “As an organization, we pride ourselves on the ability to adhere to our core Hoosier values while scaling the business globally in accordance with growing demand and the expansion of our product lines. In addition to acquiring a manufacturing facility in California, we recently opened a sales office in Bangalore, India. In December, we announced the launch of a new retail point-of-care software for health screeners that is poised to create a niche in the expanding field of population health management.”

    PTS Diagnostics currently has more than 150 employees in its flagship Indianapolis location and 86 employees in its Sunnyvale, California facility, which was acquired in late 2013. The company continues to grow much faster than the rate of industry growth, and this expansion will bring jobs to Indianapolis in the finance, marketing, chemistry, engineering, and manufacturing sectors, amongst others. Interested applicants are encouraged to monitor the PTS Diagnostics career center at ptsdiagnostics.com/career-center.html.

    According to Indiana University’s Kelley School of Business, the economic impact of Indiana’s life sciences industry has climbed to more than $63 billion and is comprised of roughly 60,000 employees – making it one of the top states for in vitro diagnostics.

    “The Browning/Duke Realty joint venture is proud to partner with PTS Diagnostics and assist them with the development of a building that is capable of meeting their growth and manufacturing needs, said Mark Hosfeld, Vice President of Leasing and Development at Duke Realty. “Indiana has a booming life sciences sector and this new global headquarters represents a continued commitment to the point-of-care technology that will further solidify their place in this rapidly growing industry.”

    About PTS Diagnostics:
    Through its People, Technology and Service, PTS Diagnostics creates health innovation that drives action and results. Since 1992, we have helped medical professionals and patients achieve better health outcomes through our accurate, precise, fast, affordable, and certified point-of-care medical devices. Healthcare professionals have used our CardioChek® products to assess cardiovascular disease risks for more than 140 million patients worldwide through lipid panel screening. And, our A1CNow® systems, which provide fast and reliable HbA1c testing, have helped physicians deliver more effective treatments to patients with diabetes. From our headquarters in the United States of America, we design, manufacture, and market our productsto more than 140 countries around the globe. For more information, visit ptsdiagnostics.com.

    About Browning
    Founded in 1977, Browning remains one of the premier development companies in Indianapolis and is engaged in the acquisition, development, construction, leasing, management, ownership and disposition of investment real estate properties, primarily in the Indianapolis metropolitan area. In total, Browning has developed and constructed more than 25 million square feet of space of bulk industrial space. To learn more, visit: www.browninginvestments.com.

    About Duke Realty Corporation
    Duke Realty Corporation owns and operates approximately 149 million rentable square feet of industrial assets in 20 key U.S. logistics markets. Duke Realty is publicly traded on the NYSE under the symbol DRE and is listed on the S&P 500. The company maintains a Baa1 rating from Moody’s Investor Service and a BBB+ rating from Standard & Poor’s Financial Services. More information about Duke Realty Corporation is available at www.dukerealty.com. Duke Realty also can be followed on Twitter, LinkedIn, Facebook and YouTube.

    Press Contact:
    Ryan Simpson, Marketing Associate
    317-870-5610
    rsimpson@ptsdiagnostics.com

    PTS Diagnostics Releases Updated A1C Home Monitoring System, Lowers Average Cost Per Test

    PTS Diagnostics Releases Updated A1C Home Monitoring System, Lowers Average Cost Per Test

    A1CNow® Self Check now comes with approximately one year’s worth of tests

    INDIANAPOLIS (Oct. 24, 2018) – PTS Diagnostics, a U.S.–based manufacturer of point-of-caretesting devices, today announced that they are updating their at-home A1CNow Self Check system by doubling the number of A1C tests per package.

    Moving from a two-count to a four-count system aligns with the American Diabetes Association’s recommendation of quarterly HbA1c testing in patients whose therapy has changed or who are not meeting glycemic goals.

    “Accurate and affordable solutions at the point of care are essential for the management of diabetes and associated comorbidities,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “We’re a leader within the point-of-care industry and are proud to help to reduce the cost of in-home testing while adhering to the recommendations of valued industry associations.”

    The increased number of tests may provide greater autonomy for people with diabetes while ensuring compliance with individualized treatment programs. This solution provides the patient with a method to inform the healthcare provider of their glycemic control without the need for frequent office visits.

    The A1CNow Self Check is a home measurement system for HbA1c, the two to three-month average of one’s blood glucose. It is trusted throughout the United States’ medical community, provides results in five minutes, has more than a 12 month shelf-life at room temperature and comes with a monitor, test cartridges, fingerstick lancets, and blood collectors.

    In addition to home usage, PTS Diagnostics envisions that providers will discover a niche for the updated product within the value-based healthcare system.

    “The A1CNow Self Check can be used in conjunction with our PTS Connect® information management solutions to routinely monitor patients,” said Steve Riendeau, Chief Commercial Officer. Increased accessibility will help support new CMS initiatives related to remote patient monitoring and increase overall patient satisfaction.”

    The four-count A1CNow Self Check is currently available online through Test Medical Symptoms At Home and in the professional setting through Cardinal Health, Fisher Scientific, Hanson Medical Systems, Henry Schein, and McKesson in the United States. The four-count is available in the European Union and will be rolled out to select countries and additional U.S. distributors in the coming months. Interested parties are encouraged to contact their local distributor, reach out to PTS Diagnostics via phone at 877-870-5610, or email PTS customer service at customerservice@ptsdiagnostics.com for more information.

    About PTS Diagnostics:
    Through its People, Technology and Service, PTS Diagnostics creates health innovation that drives action and results. Since 1992, we have helped medical professionals and patients achieve better health outcomes through our accurate, precise, fast, affordable, and certified point-of-care medical devices. Healthcare professionals have used our CardioChek® products to assess cardiovascular disease risks for more than 140 million patients worldwide through lipid panel screening. And, our A1CNow® systems, which provide fast and reliable HbA1c testing, have helped physicians deliver more effective treatments to patients with diabetes. From our headquarters in the United States of America, we design, manufacture, and market our products to more than 140 countries around the globe. For more information, visit ptsdiagnostics.com.

    Press Contact:
    Ryan Simpson, Senior Marketing Associate
    317-870-5610
    rsimpson@ptsdiagnostics.com

    PTS Diagnostics Enters Co-Branded Agreement With Rimidi

    PTS Diagnostics Enters Co-Branded Agreement With Rimidi

    Partnership with digital health leader allows for enhanced population-analytics, management of chronic conditions

    INDIANAPOLIS – PTS Diagnostics, a U.S.-based manufacturer of point-of-care testing devices, today announced that they have entered into a contractual agreement with Atlanta-based digital health and analytics company, Rimidi.

    The contract went into effect in October, 2018, and seeks to improve care and drive clinical efficiency by utilizing Connected Care, a digital condition management solution powered by Rimidi’s software. This aims to close gaps in care, and enable personalized management of diseases for individuals, population analytics for care teams, and clinical analytics for providers.

    “PTS Diagnostics has spent considerable time and effort understanding our customers’ needs related to patient outcomes, workflow improvement, and maximizing value-based payment models,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “We’ve partnered with Rimidi to better serve our customers when it comes to improved patient and provider experience and outcomes at a lower cost.”

    With unique digital dashboards for both patients and providers, Connected Care allows for enhanced patient monitoring and coaching. The joint offering of Connected Care and PTS Diagnostics A1CNow® and CardioChek® point-of-care solutions, enables the type of proactive population management required for value-based care models.

    “Rimidi’s goal is to improve the experience for both patients with chronic conditions and their physicians and care teams, ultimately improving patient outcomes and lowering costs,” said Josh Claman, CEO of Rimidi. “We cannot do that without an ecosystem of strategic partnerships like this one with PTS Diagnostics.”

    Unlike other freestanding chronic disease management platforms, Connected Care works seamlessly into the physician or care team’s workflow, integrating directly with providers’ Electronic Health Records (EHRs), leveraging emerging industry standards like SMART on FHIR. In addition, Connected Care features predictive medication modeling based on key markers from patient monitoring, enabling the potential for greater treatment plan adherence.

    “Our customers count on us to partner with quality solutions-providers and PTS Diagnostics has a proven track record of delivering point-of-care technology of the highest quality,” said Jeff Stebbins, Head of Payer Strategy and Marketing. “We could not be prouder to partner with an innovator such as Rimidi, whose technology bridges the gap between population health and personalized medicine.”

    This partnership is being unveiled in the United States and select foreign countries and will continue to grow as population health needs dictate. For more information, please reach out to PTS Diagnostics via phone at 877-870-5610, or email PTS Diagnostics customer service at customerservice@ptsdiagnostics.com for more information.

    About PTS Diagnostics:
    Through its People, Technology and Service, PTS Diagnostics creates health innovation that drives action and results. Since 1992, we have helped medical professionals and patients achieve better health outcomes through our accurate, precise, fast, affordable, and certified point-of-care medical devices. Healthcare professionals have used our CardioChek® products to assess cardiovascular disease risks for more than 140 million patients worldwide through lipid panel screening. And, our A1CNow® systems, which provide fast and reliable HbA1c testing, have helped physicians deliver more effective treatments to patients with diabetes. From our headquarters in the United States of America, we design, manufacture, and market our products to more than 130 countries around the globe. For more information, visit ptsdiagnostics.com.

    About Rimidi
    Rimidi is addressing the healthcare problem of our generation- cardiometabolic diseases, which account for 70 percent of healthcare spend. Created by doctors, Rimidi enables efficient, personalized care to forward the future of healthcare. Rimidi’s platform derives actionable insight for clinicians and care teams from individual patient data, and integrates seamlessly into provider EHR systems, optimizing clinical workflow, improving health outcomes, and reducing costs. To learn more, visit Rimidi.com.

    Press Contact:
    Ryan Simpson, Senior Marketing Associate
    317-870-5610
    rsimpson@ptsdiagnostics.com

    PTS Diagnostics Announces New Wellness Brand

    PTS Diagnostics Announces New Wellness Brand

    PreVantage family of solutions introduced for outcome-based healthcare

    INDIANAPOLIS (Nov. 8, 2018) – PTS Diagnostics, a U.S.-based manufacturer of point-of-care testing devices, today announced the upcoming global launch of PreVantage, an all-encompassing family of solutions and partnerships aimed at addressing the growing demand for the achievement of positive population health outcomes.

    The PreVantage brand was developed to address the complex needs of the multiple markets served by PTS Diagnostics. These configurable solutions are offered under singular umbrella brand and can be customized based upon unique customer needs.

    “This brand marks our transition into becoming a global wellness solutions provider,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “For more than two decades, PTS Diagnostics has partnered with leaders largely in the health industry by providing products such as our A1CNow® systems and CardioChek® analyzers, which can allow healthcare professionals to monitor diabetes, as well as assess cardiovascular disease risk. We anticipate using PreVantage to build upon these existing relationships, continue our rapid expansion into new markets, and to help shape the future of healthcare.”

    PreVantage allows PTS Diagnostics to strategically align with global healthcare changes through a unique focus on patient outcomes, lower healthcare costs, and improved clinician and patient experiences. 

    “Outcomes are the new income in many healthcare models, and point-of-care testing aligns perfectly by rapidly and accurately providing results in minutes instead of days,” said Stephen Riendeau, Chief Commercial Officer of PTS Diagnostics. “In this complex global environment, no one product or company can meet the multitude of market demands, it will take an innovative approach which challenges the way that suppliers traditionally have partnered with customers. We’re hopeful that strategic partnerships associated with PreVantage will open doors in multiple market segments and help to improve the overall state of global healthcare.”

    PreVantage is being unveiled in the United States and select countries in early 2019. It will continue to grow nationally as healthcare shifts from a fee-for-service model to merit-based incentivization. The brand will also mature globally as PTS Diagnostics assists with meeting unique healthcare needs abroad.

    Interested parties are encouraged to reach out to PTS Diagnostics via phone at 877-870-5610, or email at customerservice@ptsdiagnostics.com for more information.

    About PTS Diagnostics:
    Through its People, Technology and Service, PTS Diagnostics creates health innovation that drives action and results. Since 1992, we have helped medical professionals and patients achieve better health outcomes through our accurate, precise, fast, affordable, and certified point-of-care medical devices. Healthcare professionals have used our CardioChek® products to assess cardiovascular disease risks for more than 140 million patients worldwide through lipid panel screening. And, our A1CNow® systems, which provide fast and reliable HbA1c testing, have helped physicians deliver more effective treatments to patients with diabetes. From our headquarters in the United States of America, we design, manufacture, and market our products to more than 130 countries around the globe. For more information, visit ptsdiagnostics.com.

    Press Contact:
    Ryan Simpson, Senior Marketing Associate
    317-870-5610 – rsimpson@ptsdiagnostics.com